MARKET

ALLK

ALLK

Allakos
NASDAQ
7.44
+0.17
+2.34%
After Hours: 7.44 0 0.00% 16:34 11/25 EST
OPEN
7.20
PREV CLOSE
7.27
HIGH
7.57
LOW
7.18
VOLUME
313.85K
TURNOVER
0
52 WEEK HIGH
86.95
52 WEEK LOW
2.535
MARKET CAP
633.91M
P/E (TTM)
-1.1000
1D
5D
1M
3M
1Y
5Y
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment w...
GlobeNewswire · 11/10 14:02
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Benzinga · 11/09 10:08
DuPont, Expeditors International, Planet Fitness And Other Big Gainers From Tuesday
Benzinga · 11/09 07:53
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/08 18:41
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 11/08 17:51
IceCure, Allakos top healthcare gainers; NanoString, R1 RCM lead losers' pack
Seekingalpha · 11/08 15:01
Allakos GAAP EPS of -$0.53 beats by $0.23
Seekingalpha · 11/07 21:58
Allakos Q3 EPS $(0.53) Beats $(0.78) Estimate
Benzinga · 11/07 21:43
More
About ALLK
Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Webull offers kinds of Allakos Inc stock information, including NASDAQ:ALLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALLK stock methods without spending real money on the virtual paper trading platform.